Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)
Launched by FRENCH SOCIETY FOR INTENSIVE CARE · Jan 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PETUNIA trial is a study that aims to understand how antibiotics are used to treat patients with Ventilator-Associated Pneumonia (VAP), a lung infection that can occur in people who are on a ventilator. This research is being conducted by the French Society of Intensive Care, and it is currently looking for participants. To be eligible for the trial, patients need to be at least 18 years old, receiving care in an Intensive Care Unit (ICU), and have been on a ventilator for more than 48 hours while starting new antibiotics for a suspected case of VAP.
If you or a loved one meets these criteria, participating in this trial could help improve the way VAP is treated in critically ill patients. Participants will be asked to provide information about their treatment and health, which may help doctors learn more about the best practices for using antibiotics in these situations. It’s important to note that patients who have certain conditions or previous participation in similar studies may not be eligible. If you have any questions or concerns about joining, please feel free to discuss them with your healthcare team.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Admission to the ICU
- • Intubation and duration of invasive mechanical ventilation \> 48 hours
- • Initiation of new antibiotic therapy to treat a first suspicion of Ventilator-Associated Pneumonia (VAP)
- Exclusion Criteria:
- • Presence of a decision to limit active therapeutic measures at the time of initiating antibiotic therapy
- • Organ donor
- • Prior inclusion in the study during a previous stay in the intensive care unit (a patient cannot be included multiple times)
- • Participation in an interventional study focusing on the management of VAP and directly impacting antibiotic therapy practices
- • Patient and/or family opposition to participation
- • Lack of affiliation with a social security system
About French Society For Intensive Care
The French Society for Intensive Care (Société Française de Réanimation, SFR) is a leading organization dedicated to advancing the field of intensive care medicine through research, education, and collaboration. As a prominent clinical trial sponsor, the SFR aims to enhance patient outcomes by facilitating innovative studies that address critical issues in intensive care practices. Committed to fostering interdisciplinary cooperation among healthcare professionals, the society emphasizes the importance of evidence-based approaches and actively promotes the dissemination of knowledge within the intensive care community. Through its rigorous oversight and support of clinical research initiatives, the SFR plays a vital role in shaping the future of intensive care in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, Haut De France, France
Patients applied
Trial Officials
Anahita Rouzé, MD
Principal Investigator
French Intensive Care Society
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported